In patients with type 2 diabetes, the risk for chronic kidney disease differed among users of SGLT2 inhibitors, GLP-1 receptor agonists, DPP-4 inhibitors, and sulfonylurea.

FDA drug alerts in endocrinology, including drug approvals, drug warnings, FDA medical device recalls, and FDA drug label ...

KBP Biosciences Pte. Ltd. (the "Company") today issued a statement addressing a recent decision by the Singapore International Commercial Court ("SICC"), which granted an injunction sought by Novo ...

Ahead of World Obesity Day, we examine the impact of the game-changing drugs that control appetite. Increasingly being taken ...

Patient advocacy group Patients for Affordable Drugs (P4AD) yesterday filed its fourth amicus brief defending the Biden ...

Lexaria executing a triple-pronged strategy in obesity and diabetesSemaglutide recently approved to treat chronic kidney disease KELOWNA, BC / ACCESS Newswire / February 27, 2025 / Lexaria Bioscience ...

The initiatives to improve healthcare access — including Ayushman Bharat, which provides financial protection and better ...

The five stages of chronic kidney disease (CKD) indicate how well the kidneys are working, ranging from stage 1 (mild kidney ...

People with a high body weight living in England can now access subsidized weight-loss drugs to treat their obesity. This includes Wegovy (the weight-loss dose of Ozempic, or semaglutide) and Mounjaro ...

The Food and Drug Administration has determined that the shortage of Wegovy® (semaglutide) and Ozempic® (semaglutide) is resolved.